↑ トップへ　← 戻る

 Drug（薬物リスト） DrugBank | All Description Patterns💬 Info on mouse-over

e.g. Sirolimus, アダリムマブ

ABCDEFGH I JKLMNOPQRSTUVWXYZother

147 / 17,542 descriptions

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY
On map, Yellow: Drug target genes		 指定難病告示番号
1 Abatacept active treatment Abatacept 1件: D03203 💬 2件: CD80, CD86 💬 12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 1件: 50 💬
2 Abatacept delayed-onset treatment Abatacept 1件: D03203 💬 2件: CD80, CD86 💬 12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 1件: 50 💬
3 Active investigational treatment ent-01 - - - - 1件:  6  💬
4 Active treatment group 7% hypertonic saline - - - - 1件: 299 💬
5 Baseline treatment - - - - 1件: 13 💬
6 Bdmard treatment - - - - 1件: 271 💬
7 Behavioral: co-op treatment protocol - - - - 1件:  6  💬
8 Behavioral: conservative treatment - - - - 1件: 291 💬
9 Best medical treatment - - - - 1件:  6  💬
10 Best médical treatment - - - - 1件:  6  💬
11 Bisphosphonate treatment - - - - 2件: 113, 299 💬
12 Botulism toxin treatment - - - - 1件: 161 💬
13 Break in l-carnitine treatment Levocarnitine 3件: D02030, D02176, D04713 💬 - - 1件: 316 💬
14 Classic dmards treatment group - - - - 1件: 46 💬
15 Clobetasol propionate cream treatment Clobetasol 2件: D01272, D07715 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 162 💬
16 Combination product: active treatment with dual therapy - - - - 1件:  2  💬
17 Corticosteroid treatment (methylprednisolone or prednisolone) Methylprednisolone 14件: D00407, D00472, D00751, D00979, D00980, D00981, D00982, D01239, D01998, D02156, D03301, D05000, D05001, D05002 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 64 💬
18 Current lipid-lowering treatment - - - - 1件: 79 💬
19 Detoxifying agents for antineoplastic treatment - - - - 1件: 299 💬
20 Dopamine agonist treatment Dopamine 2件: D00633, D07870 💬 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 1件: 74 💬
21 Drug treatment - - - - 4件: 46, 51, 74, 271 💬
22 Era as specific pah treatment - - - - 1件: 86 💬
23 Etanercept treatment Etanercept 1件: D00742 💬 2件: LTA, TNF 💬 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 1件: 46 💬
24 Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab) Rituximab 1件: D02994 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 1件: 222 💬
25 Fibrate treatment - - - - 1件: 160 💬
26 Foliglurax 10 mg (treatment a) Foliglurax - - - 1件:  6  💬
27 Foliglurax 30 mg (treatment b) Foliglurax - - - 1件:  6  💬
28 From august 2020 'no additional treatment' - - - - 1件: 51 💬
29 Genotropin (somatropin) is a growth hormone treatment. it is an exact copy of the natural growth hormone that our bodies make. the main difference is that genotropin is man-made. Somatotropin 1件: D02691 💬 1件: GHR 💬 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 1件: 193 💬
30 Glucocorticoid treatment - - - - 1件: 41 💬
31 Golimumab treatment optimization. Golimumab 1件: D04358 💬 1件: TNF 💬 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 1件: 97 💬
32 Hcq/cq and cab combined treatment - - - - 1件: 74 💬
33 Herbal treatment (sa100) - - - - 1件: 97 💬
34 Hyperpolarized 129 xenon gas comparing idiopathic pulmonary fibrosis (ipf) treatment Xenon 2件: D01901, D06339 💬 - - 1件: 85 💬
35 Immunosuppressive treatment - - - - 1件: 66 💬
36 Immunosuppressive treatment (eg, rituximab) Rituximab 1件: D02994 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 1件: 64 💬
37 In double-blind phase: treatment with tofacitinib Tofacitinib 1件: D09970 💬 4件: JAK1, JAK2, JAK3, TYK2 💬 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 1件: 107 💬
38 In open-label phase: treatment with tofacitinib Tofacitinib 1件: D09970 💬 4件: JAK1, JAK2, JAK3, TYK2 💬 35件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 1件: 107 💬
39 Interferon beta treatment to add-on atorvastatin treatment Atorvastatin 3件: D00258, D00887, D07474 💬 1件: HMGCR 💬 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 1件: 13 💬
40 Iv treatment with igsc, 10% - - - - 1件: 65 💬
41 Lapaquistat acetate and current lipid-lowering treatment Acetate - - - 1件: 79 💬
42 Lumacaftor-ivacaftor treatment Ivacaftor 2件: D09916, D10134 💬 1件: CFTR 💬 8件: ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 1件: 299 💬
43 Metformin treatment Metformin 2件: D00944, D04966 💬 2件: PRKAA1, PRKAA2 💬 19件: AMPK signaling pathway, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 1件: 46 💬
44 Methotrexate treatment Methotrexate 2件: D00142, D02115 💬 2件: DHFR, DHFR2 💬 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 2件: 41, 46 💬
45 Mk0812 / duration of treatment: 12 weeks - - - - 1件: 46 💬
46 Msc treatment - - - - 1件: 49 💬
47 Msc treatment 01 - - - - 1件: 96 💬
48 Msc treatment 02 - - - - 1件: 96 💬
49 Natalizumab treatment Natalizumab 1件: D06886 💬 1件: ITGA4 💬 14件: Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 1件: 13 💬
50 Nifurtimox-eflronithine combination treatment (nect) Nifurtimox 1件: D00833 💬 - - 1件: 65 💬
51 Nusinersen treatments Nusinersen 1件: D10881 💬 1件: SMN2 💬 1件: RNA transport 1件:  3  💬
52 Oc oral solution treatment a - - - - 1件:  6  💬
53 Oc oral solution treatment b - - - - 1件:  6  💬
54 Oc oral solution treatment c - - - - 1件:  6  💬
55 Oc oral solution treatment d - - - - 1件:  6  💬
56 Only 1 arm: treatment with msc-afp - - - - 1件: 96 💬
57 Optimized antiparkinsonian treatment - - - - 1件:  6  💬
58 Oral anticoagulant treatment - - - - 1件: 86 💬
59 Other parkinson's disease treatments - - - - 1件:  6  💬
60 Other: adalimumab treatment Adalimumab 1件: D02597 💬 1件: TNF 💬 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 1件: 151 💬
61 Other: best medical treatment - - - - 1件:  6  💬
62 Other: control wound treatment - - - - 1件: 36 💬
63 Other: crohn's disease treatment-with-eating diet (cd-treat diet) - - - - 1件: 96 💬
64 Other: current treatment - - - - 1件: 46 💬
65 Other: dead sea solar and water treatment Water 1件: D00001 💬 - - 1件: 46 💬
66 Other: diet treatment - - - - 1件: 240 💬
67 Other: intensify treatment with the existing drug - - - - 2件: 96, 97 💬
68 Other: motor assessments before taking regular pd treatment - - - - 1件:  6  💬
69 Other: motor assessments on regular pd treatment - - - - 1件:  6  💬
70 Other: multidisciplinary intensive rehabilitation treatment - - - - 1件:  6  💬
71 Other: no active treatment - - - - 1件: 274 💬
72 Other: no anti-inflammatory treatment - - - - 1件: 271 💬
73 Other: no it treatment - - - - 1件: 19 💬
74 Other: no treatment - - - - 2件: 53, 256 💬
75 Other: no treatment arm - - - - 1件: 13 💬
76 Other: no treatment given - - - - 1件: 78 💬
77 Other: observation of ocrelizumab as treatment in rrms patients Ocrelizumab 1件: D05218 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 1件: 13 💬
78 Other: on-demand treatment - - - - 1件: 299 💬
79 Other: other: symptomatic treatment of als - - - - 1件:  2  💬
80 Other: sle treatment - - - - 1件: 49 💬
81 Other: standard steroid treatment - - - - 1件: 113 💬
82 Other: standard treatment - - - - 1件: 227 💬
83 Other: standard treatment according to the clinical protocols - - - - 1件: 49 💬
84 Other: usual drug treatment of parkinson's disease - - - - 1件:  6  💬
85 Plasma from healthy young people treatment + riluzole Riluzole 1件: D00775 💬 14件: GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 23件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term depression, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Retrograde endocannabinoid signaling, Spinocerebellar ataxia, Systemic lupus erythematosus, Transcriptional misregulation in cancer, cAMP signaling pathway 1件:  2  💬
86 Ppi treatment - - - - 1件: 299 💬
87 Prednisone and ustekinumab treatment Prednisone 2件: D00473, D09214 💬 4件: IL12A, IL12B, IL23A, NR3C1 💬 27件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Neuroactive ligand-receptor interaction, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 1件: 41 💬
88 Prednisone treatment Prednisone 1件: D00473 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 41 💬
89 Probiotic treatment - - - - 1件: 294 💬
90 Procedure: surgery treatment - - - - 1件: 291 💬
91 Procedure: transsphenoidal surgery treatment - - - - 1件: 74 💬
92 Procedure: treatment according to current standards without knowledge of serum infliximab and anti-infliximab ab status Infliximab 1件: D02598 💬 1件: TNF 💬 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 1件: 96 💬
93 Propranolol treatment Propranolol 2件: D00483, D08443 💬 3件: ADRB1, ADRB2, ADRB3 💬 11件: Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, cAMP signaling pathway, cGMP-PKG signaling pathway 1件: 227 💬
94 Regular treatment - - - - 1件: 97 💬
95 Repository corticotropin injection -treatment extension Corticotropin 1件: D00146 💬 1件: MC2R 💬 5件: Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Neuroactive ligand-receptor interaction, cAMP signaling pathway 1件: 84 💬
96 Routine treatment of cd - - - - 1件: 96 💬
97 Sc treatment with igsc, 10% with rhuph20 followed by iv/igsc, 10% only (safety) - - - - 1件: 65 💬
98 Sc treatment with igsc, 10% with rhuph20 followed by sc/igsc, 10% only (safety) - - - - 1件: 65 💬
99 Simvastatin treatment for 28 days Simvastatin 1件: D00434 💬 1件: HMGCR 💬 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 1件: 299 💬
100 Standard of care treatment - - - - 2件: 245, 246 💬
101 Standard steroid treatment - - - - 1件: 85 💬
102 Standard treatment with a conventional drug - - - - 1件: 13 💬
103 Standrd of care treatment - - - - 1件: 64 💬
104 Symptomatic treatment (converting enzyme inhibitor, angiotensin ii, anti-renin, aldosterone antagonist diuretic, beta blocker, calcium inhibitor, statin) Aldosterone 3件: D00150, D02014, D10528 💬 3件: AGTR1, AGTR2, NR3C2 💬 17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Aldosterone-regulated sodium reabsorption, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 1件: 222 💬
105 Symptomatic treatment, steroids, immunosuppressive agents( azathioprine, tacrolimus, mycophenolate mofetil) Azathioprine 8件: D00107, D00238, D00752, D03033, D05094, D05095, D05096, D08556 💬 7件: IMPDH1, IMPDH2, PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 35件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Drug metabolism - other enzymes, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Purine metabolism, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 1件: 11 💬
106 Symptomatic treatment, steroids, immunosuppressive agents, plasma exchange(pe), intravenous immunoglobulin(ivig) Human immunoglobulin G - - - 1件: 11 💬
107 Systemic non-biological treatments - - - - 2件: 46, 271 💬
108 The comprehensive treatment regimen of traditional chinese medicine - - - - 1件: 222 💬
109 The standard steroid treatment, plasma exchange and rituximab Rituximab 1件: D02994 💬 1件: MS4A1 💬 1件: Hematopoietic cell lineage 1件: 85 💬
110 Time delay treatment of botulinum toxin - - - - 1件: 149 💬
111 Tl011, anti cd20, for the treatment of rheumatoid arthritis - - - - 1件: 46 💬
112 Tocilizumab treatment Tocilizumab 1件: D02596 💬 1件: IL6R 💬 12件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 1件: 41 💬
113 Traditional treatment of cgd and tb - - - - 1件: 65 💬
114 Traditional treatments - - - - 1件: 97 💬
115 Treatment - - - - 2件: 41, 299 💬
116 Treatment a - - - - 2件: 34, 46 💬
117 Treatment algorithm a - - - - 1件: 97 💬
118 Treatment algorithm b - - - - 1件: 97 💬
119 Treatment algorithm c - - - - 1件: 97 💬
120 Treatment as usual (tau) - - - - 1件: 85 💬
121 Treatment b - - - - 2件: 34, 46 💬
122 Treatment bx1514m - - - - 1件: 58 💬
123 Treatment c - - - - 2件: 34, 46 💬
124 Treatment d - - - - 1件: 34 💬
125 Treatment defined only by active substance - - - - 1件: 50 💬
126 Treatment i - - - - 1件: 46 💬
127 Treatment ii - - - - 1件: 46 💬
128 Treatment iii - - - - 1件: 46 💬
129 Treatment of mtx - - - - 1件: 46 💬
130 Treatment of mtx and hcq - - - - 1件: 46 💬
131 Treatment of mtx and twhf - - - - 1件: 46 💬
132 Treatment of tcm - - - - 1件: 46 💬
133 Treatment of twhf - - - - 1件: 46 💬
134 Treatment phase group 4 - - - - 1件: 113 💬
135 Treatment systemic therapy (prednisone) Prednisone 1件: D00473 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 162 💬
136 Treatment with adalimumab Adalimumab 1件: D02597 💬 1件: TNF 💬 65件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 1件: 96 💬
137 Treatment with azathioprin - - - - 1件: 95 💬
138 Treatment with mycophenolat mofetil - - - - 1件: 95 💬
139 Treatment with polyethylene glycol (macrogol 4000) Polyethylene glycol 1件: D03370 💬 - - 1件: 299 💬
140 Treatment with systemic therapy (doxycycline) Doxycycline 5件: D00307, D02129, D03903, D03904, D07876 💬 - - 1件: 162 💬
141 Treatment with systemic therapy (methotrexate) Methotrexate 2件: D00142, D02115 💬 2件: DHFR, DHFR2 💬 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 1件: 162 💬
142 Treatment with systemic therapy (prednisone) Prednisone 1件: D00473 💬 1件: NR3C1 💬 1件: Neuroactive ligand-receptor interaction 1件: 162 💬
143 Treatment with topical superpotent corticosteroid therapy - - - - 1件: 162 💬
144 Untreated to atorvastatin treatment Atorvastatin 3件: D00258, D00887, D07474 💬 1件: HMGCR 💬 4件: AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 1件: 13 💬
145 Usual dopaminergic per os treatment - - - - 1件:  6  💬
146 Vancomycin pre-treatment Vancomycin 2件: D00212, D00926 💬 - - 1件: 97 💬
147 Viral load driven treatment interruption - - - - 1件: 265 💬

先頭へ